Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Sep 1;43(9):1165-1170.
doi: 10.1097/ICO.0000000000003527. Epub 2024 Mar 22.

Topical Losartan for Treating Corneal Haze After Ultraviolet-A/Riboflavin Collagen Cross-Linking

Emily Grace Rodgers  1 , Zaina Al-Mohtaseb  1 , Allison J Chen  2
Affiliations
Case Reports

Topical Losartan for Treating Corneal Haze After Ultraviolet-A/Riboflavin Collagen Cross-Linking

Emily Grace Rodgers et al. Cornea. .

Abstract

Purpose: The purpose of this study was to report our first clinical experience using topical losartan for the treatment of severe corneal haze after epithelium-off corneal cross-linking (CXL).

Methods: A 20-year-old man presented with clinically significant corneal haze in the right eye 1 month following Ultraviolet-A/Riboflavin Epithelium-off Collagen CXL. Haze progressed to a deep stromal scar, and vision was 20/150 with no improvement on refraction, 60 days after CXL. After unsuccessful treatment with topical corticosteroids, the patient elected to start off-label treatment with topical losartan 0.8 mg/mL, administered 6 times per day.

Results: After 3 months of initiating topical losartan, the right eye vision improved to preoperative vision of 20/40-1. Corneal haze was significantly reduced as observed on slitlamp examination and on Scheimpflug corneal tomography (Pentacam; OCULUS, Inc. Arlington, WA).

Conclusions: Topical losartan, a transforming growth factor-β inhibitor, is a potential treatment in clinically significant corneal haze following epithelium-off corneal CXL. This clinical experience highlights the potential efficacy of topical losartan as a novel therapeutic option in such cases, but further clinical studies are needed.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding or conflicts of interest to disclose.

References

    1. Santodomingo-Rubido J, Carracedo G, Suzaki A, et al. Keratoconus: an updated review. Cont Lens Anterior Eye. 2022;45:101559.
    1. Ferdi AC, Kandel H, Nguyen V, et al. Five-year corneal cross-linking outcomes: a save sight keratoconus registry study. Clin Exp Ophthalmol. 2023;51:9–18.
    1. Greenstein SA, Hersh PS. Corneal crosslinking for progressive keratoconus and corneal ectasia: summary of US multicenter and subgroup clinical trials. Transl Vis Sci Technol. 2021;10:13.
    1. Raiskup F, Hoyer A, Spoerl E. Permanent corneal haze after riboflavin-UVA-induced cross-linking in keratoconus. J Refract Surg. 2009;25:S824–S828.
    1. de Oliveira RC, Tye G, Sampaio LP, et al. TGFβ1 and TGFβ2 proteins in corneas with and without stromal fibrosis: delayed regeneration of apical epithelial growth factor barrier and the epithelial basement membrane in corneas with stromal fibrosis. Exp Eye Res. 2021;202:108325.

Publication types

MeSH terms

LinkOut - more resources